(Q30625335)

17 August 2017

Pharmacokinetic-pharmacodynamic determinants of oseltamivir efficacy using data from phase 2 inoculation studies (English)

1 reference

17 August 2017

1 reference

1 reference

1 reference

C R Rayner

1

1 reference

17 August 2017

C C Bulik

2

1 reference

17 August 2017

M A Kamal

3

1 reference

17 August 2017

D K Reynolds

4

1 reference

17 August 2017

S Toovey

5

1 reference

17 August 2017

J P Hammel

6

1 reference

17 August 2017

P F Smith

7

1 reference

17 August 2017

S M Bhavnani

8

1 reference

17 August 2017

S A Van Wart

9

1 reference

17 August 2017

P G Ambrose

10

1 reference

17 August 2017

A Forrest

11

1 reference

17 August 2017

language of work or name

English

0 references

publication date

13 May 2013

1 reference

Antimicrobial Agents and Chemotherapy

17 August 2017

10

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

17 August 2017

57

1 reference

17 August 2017

8

1 reference

17 August 2017

3478-3487

1 reference

Effect of double dose oseltamivir on clinical and virological outcomes in children and adults admitted to hospital with severe influenza: double blind randomised controlled trial

17 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3719781

Population pharmacokinetics of oseltamivir: pediatrics through geriatrics

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3719781

Zanamivir, at 600 milligrams twice daily, inhibits oseltamivir-resistant 2009 pandemic H1N1 influenza virus in an in vitro hollow-fiber infection model system

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3719781

Effect of half-life on the pharmacodynamic index of zanamivir against influenza virus delineated by a mathematical model

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3719781

Prediction of the pharmacodynamically linked variable of oseltamivir carboxylate for influenza A virus using an in vitro hollow-fiber infection model system

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3719781

Efficacy of oseltamivir therapy in ferrets inoculated with different clades of H5N1 influenza virus

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3719781

Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3719781

Oral oseltamivir in human experimental influenza B infection.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3719781

Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3719781

Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3719781

Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3719781

25 November 2018

Identifiers

DOI

10.1128/AAC.02440-12

1 reference

17 August 2017

1 reference

17 August 2017

PubMed publication ID

23669386

1 reference